Table 4 BNCT clinical trials using epithermal neutron beams for patients with recurrent or untreated unresectable head and neck cancer
Medical institution | Neutron source | Treatment dates | Tumor type & No. of patients | Boron compounda | Clinical outcome | Ref. |
|---|---|---|---|---|---|---|
Osaka University, Oral & Maxillofacial Surgery II, Osaka, Japan | KURR (Kyoto University Research Reactor, Osaka, Japan) or JRR-4, Japan Atomic Energy Agency, Tokai Research Establishment, Ibaraki, Japan | 2001-2007 | 26 rH&N | BSH 5 g & BPA 250 mg/kg in 1 h Or BPA 250–500 mg/kg in 1–2 h | MeST: 7.9 mos. post BNCT | |
PR: 39% | ||||||
CR: 46% | ||||||
2 & 4 y OS: 37%, | ||||||
6 y OS: 32% | ||||||
Osaka Medical College, Osaka, Japan | KURR | 2005-2008 | 6 rOC | BPA 500 mg/kg (200 mg/kg h × 2 h; 100 mg/kg h × ~1 h during irradiation) | PR: 67% | |
CR: 17% | ||||||
Kyoto University Research Reactor Institute (KURRI), Kyoto University, Osaka, Japan | KURR | 2001-2007 | 49 rH&N | BSH & BPA 250–500 mg/kg | PR: 29%, CR: 28% | |
13 urH&N | ||||||
MeST: 10.1 mos. (n = 53) | ||||||
2 y OS: 24% | ||||||
Kawasaki Medical School, Kurashiki, Japan | KURR or JRR-4 | 2003-2007 | 10 rSqCC | BPA 500 mg/kg (200 mg/kg h × 2 h; 100 mg/kg h × ~1 h during irradiation) | PR: 35% | |
7 rnSqCC | ||||||
3 nSqCC | CR: 55% | |||||
2 y OS: 32.3% | ||||||
JRR-4 | 2005-2008 | 10 H&N MM | BPA 500 mg/kg | PR: 50% | [120] | |
CR: 40% | ||||||
Helsinki University Central Hospital, Helsinki, Finland | FiR-1, VTT Technical Research Centre, Espoo, Finland | 2003-2008 | 24 rSqCC | BPA 400 mg/kg in 2 h | PR: 31% | [7] |
CR: 45% | ||||||
6 rnSqCC | ||||||
MeST: 13 mos. post BNCT | ||||||
2 y OS: 30% | ||||||
2010 | 1 ur PDC | BPA 400 mg/kg in 2 h | CR: 1/1 | [121] | ||
BNCT + Chemo-RT (IMRT + SRT) with cetuximab and cisplatin | ||||||
Taipei Veterans General Hospital, Taipei, Taiwan | THOR, National Tsing Hua University, Hsinchu, Taiwan | 2010-2011 | 10 rH&N | BPA ~450 mg/kg (180 mg/kg h × 2 h; 90 mg/kg h × ~1 h during irradiation) | PR: 40% | |
CR: 30% |